STRO - SUTRO BIOPHARMA, INC.

22.5
1.190   5.289%

Share volume: 220,738
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$21.31
1.19
0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
10%
Profitability 0%
Dept financing 12%
Liquidity 37%
Performance 13%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
9.52%
1 Month
44.97%
3 Months
164.86%
6 Months
2,190.54%
1 Year
1,430.61%
2 Year
378.72%
Key data
Stock price
$22.50
P/E Ratio 
0.00
DAY RANGE
$20.72 - $22.76
EPS 
-$2.55
52 WEEK RANGE
$0.52 - $22.76
52 WEEK CHANGE
$1,400.00
MARKET CAP 
73.618 M
YIELD 
N/A
SHARES OUTSTANDING 
85.135 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
3.65
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$112,965
AVERAGE 30 VOLUME 
$137,860
Company detail
CEO: William J. Newell
Region: US
Website: sutrobio.com
Employees: 240
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Sutro Biopharma, Inc. focuses on creating protein therapeutics for cancer and autoimmune disorders. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma.

Recent news